Day: June 14, 2022

CNH Industrial has published the companion guide to its 2021 Sustainability Report, A Sustainable Year. The publication is also available as an interactive online magazine. Visit publications.cnhindustrial.com/a-sustainable-year-2021 to learn more about how the Company and its people proactively work to make the world a better place.

London, June 14, 2022

CNH Industrial (NYSE: CNHI / MI: CNHI) has redoubled its commitment to a more sustainable future, as evidenced by the sixth edition of A Sustainable Year which highlights a selection of sustainability initiatives accomplished in 2021.

It complements the earlier publication of the 2021 Sustainability Report, providing a reader-friendly snapshot of the Company’s major social, economic, and environmental activities as well as its strategic sustainability targets.

A Sustainable Year showcases some of the projects and initiatives that are enabling CNH Industrial to pursue its sustainability strategy. Highlights include CASE Construction Equipment’s beach care project to tackle plastic waste and raise awareness, and the Company’s program to install solar panels on the roofs of all manufacturing plants by 2030. It also details the New Holland brand’s e-Source, a new plug-in system which transforms mechanical energy generated by a tractor into electricity to power implements, consequently reducing carbon emissions, improving safety standards, and saving fuel.

Furthermore, the publication provides updates on how the Company is engaged with its people and communities at large, promoting Diversity and Inclusion initiatives and supporting its customers on their own sustainability journeys.

These stories are testament to CNH Industrial’s leading role in corporate sustainability. The Company continues to be acknowledged for its commitment, including 11 consecutive years of being named as an Industry Top Scorer in the Dow Jones Sustainability World and Europe Indexes.

Download the latest edition of A Sustainable Year in PDF HERE
Peruse the interactive version HERE

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnhindustrial.com

For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Media contacts:

Rebecca Fabian	Anna Angelini
North America	United Kingdom
Tel. +1 312 515 2249	Tel. +44 (0)7725 826 007

mediarelations@cnhind.com

Attachments

• 20220614_PR_CNH_Industrial_ASY
• A Sustainable Year 2021

The new technology offering gives clients unprecedented flexibility in managing projects

NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) — Epiq, a technology-enabled services leader to global corporate legal departments and law firms, announced today the launch of Epiq Choice and a corresponding milestone: celebrating 15 years since pioneering eDiscovery managed services. Senior Vice President of eDiscovery Services, Scott Berger, who won a Lifetime Achievement award at this year’s Leaders in Tech Law Awards during Legalweek NY, led a team that originally conceived of and launched eDiscovery managed services in 2007. Their goal was to take a concept known to other industries and apply it to the legal technology and support industry. It was designed to combat the unpredictability of price, service quality, and technology utilization that was prevalent in legal at the time, and the effort has led to major changes in the way legal does business. Epiq Choice is the next step in that journey of providing flexibility and value to clients.

Epiq Choice is in keeping with Epiq’s reputation as a trailblazer and leading provider in eDiscovery. With it, leaders in corporations and law firms can take advantage of multiple eDiscovery tools in one place with easy access via the Epiq Service Cloud, and with a predictable monthly fee. Epiq Choice provides clients with the existing eDiscovery tools they are accustomed to, along with the ability to explore new technologies, without having to make specific commitments or investments to exact tools and volumes.

“For many of our clients, Epiq Choice is the answer to the unknown,” said Scott Berger. “The tools and technologies within our industry are rapidly evolving, and in some cases, a new tool might be the perfect fit for a specific matter. Epiq Choice allows clients to benefit from our own investments in platforms and training without having to shoulder the risk themselves. Our history and spirit of innovation made us The Leader in eDiscovery Managed Services^TM, and Epiq Choice is the next evolution in the journey.”

The eDiscovery platforms currently available via Epiq Choice include Epiq Discovery, NUIX, Reveal, Relativity, and RelativityOne. Epiq Choice is fully integrated into the Epiq Service Cloud, which provides a modernized digital experience for working with Epiq, along with centralized and secure single-sign-on capabilities for a law firm or legal department’s entire tech-stack via Epiq Access.

The innovative spirit that drives Epiq’s eDiscovery Managed Services team and has led to its growth was validated earlier this year by the Leaders in Legal Tech Law Awards Lifetime Achievement recognition.

“It is appropriate that the award for Scott came in the same year that Epiq commemorates the 15^th anniversary of our managed service offering and launches this exciting new technology,” said Roger Pilc, president and general manager for Epiq’s Legal Solutions business. “Under his leadership, the Epiq team has become dominant in the space, growing from fewer than 20 people to more than 250 professionals dedicated solely to the managed services program, making it the largest and most experienced pool of eDiscovery experts available. The group partners with more than 100 clients and leads the industry in leveraging innovation such as AI model libraries on their behalf. We could not be more proud of all that this team has accomplished.”

To learn more about how Epiq’s eDiscovery Managed Services, visit us here.

About Epiq
Epiq, a global technology-enabled services leader to the legal industry and corporations, takes on large-scale, increasingly complex tasks for corporate counsel, law firms and business professionals with efficiency, clarity and confidence. Clients rely on Epiq to streamline the administration and transformation of business and legal operations, class action and mass tort, court reporting, eDiscovery, regulatory, compliance, restructuring and bankruptcy matters. Epiq subject-matter experts and technologies create efficiency through expertise and deliver confidence to high-performing clients around the world. Learn more at www.epiqglobal.com.

Press Contact Candice Russell Epiq +1 203 461 5852 Candice.russell@epiqglobal.com

Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health

CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) — Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, today announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been acting Chief Executive Officer since 2020 will continue as Chair of the Board.

Professor Sir Shankar Balasubramanian FRS, co-founder of Cambridge Epigenetix, said, “We welcome Peter and his vast industry experience and valuable relationships to lead Cambridge Epigenetix at this critical juncture. The founders, Gail and the entire Board are delighted to have Peter’s leadership as we seek to grow the company into its full potential.”

Mr. Fromen joins the company from PacBio (NASDAQ: PACB) where he served as Chief Commercial Officer (CCO), based in London. During his tenure, he transformed the commercial organization and led the team to achieve record levels of sales, growing revenues by 65% and more than doubling the company’s installed base of sequencers.

“Peter brings global leadership and broad commercial expertise leading key functions in product marketing, product management, market development, sales, service, and support. His record of building, growing, and retaining world-class teams is particularly important to us as we prepare for the future,” shared Gail Marcus. “We are confident Peter and his leadership style will enhance our innovation-centric culture which- is built on integrity, humility and diversity.”

Prior to PacBio, Mr. Fromen worked at Illumina where he held numerous leadership positions across the finance and commercial organizations including investor relations, product marketing, market development, and enterprise sales. He built the Company’s first investor relations and market development functions and had a leading role in launching the Company’s HiSeq X Ten Sequencing System which delivered the first $1000 human whole genome. Notably, while serving as the company’s Global Vice President of Population Genomics and Precision Health, Mr. Fromen oversaw Illumina’s partnership with Genomics England and the National Health System (NHS) to execute the 100,000 Genomes Project which subsequently led to the commissioning of whole genome sequencing in the NHS for rare disease and certain cancers.

“The founders of Cambridge Epigenetix had the foresight and wisdom to envision the potential of epigenetics before anyone else, attracting an industry leading Board and group of investors. This exceptional team has developed one of the most exciting technology platforms I have seen in my career. It has the potential to dramatically reduce the cost of capturing novel epigenetic information while preserving its genetic context, all in a single sequencing workflow,” said Peter Fromen. “I am deeply excited to join Cambridge Epigenetix and lead the company to its next stage of growth, empowering customers to realize the full contribution of epigenetics to human health.”

About Cambridge Epigenetix

Cambridge Epigenetix, a life sciences tools and technology company, is revolutionizing sequencing by delivering new dimensions of information from DNA to identify and treat disease earlier, harnessing the potential to transform life sciences and medicine. The commercial-stage company’s platform provides more information with greater efficiency at higher quality and lower cost than standard next generation sequencing technologies. Easily integrating into existing sequencers, the company’s products allow the user to simultaneously see genetic and epigenetic information in a single workflow. This information can be used to detect, diagnose, treat, and understand disease. Based in Cambridge, UK, amongst the Company’s founders is a pioneer in DNA sequencing, intent on leading the next great leap forward in genomics. To learn more, please visit https://cambridge-epigenetix.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/71ea248c-5c35-478c-8817-a67392de430a

Business Contact
enquiries@cegx.co.uk

Media Contact
media@cegx.co.uk

Medical affairs teams can now access the scientific activities of nearly 13 million experts globally across all therapeutic areas in a single platform

FRAMINGHAM, Mass., June 14, 2022 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the general availability of Monocl ExpertInsight 2.0, the next generation of the company’s expert identification product, and a new mobile app, Monocl ExpertGO. These new offerings give medical affairs professionals access to nearly 13 million expert profiles globally so they can more quickly identify and engage the right scientific experts to provide critical insights that can accelerate the drug development process.

Monocl ExpertInsight 2.0 provides an optimized user experience that helps medical affairs teams increase productivity, streamline workflows and develop more informed medical strategies. Monocl ExpertInsight 2.0 equips medical affairs teams with:

• Live filters that provide an overview of scientific activity with real-time updates and filters by expert and/or therapeutic area
• Advanced search functionality to identify experts more easily in specific disease areas
• Dynamic key opinion leader (KOL) mapping, which displays the location of experts in granular detail down to the city level

Existing clients will get access to these new features at no additional cost as part of their existing Monocl ExpertInsight subscription.

“We’re passionate about helping medical affairs teams find the right experts who can help accelerate time to market for a new drug or medical device,” said Robert Musslewhite, president of Definitive Healthcare. “With today’s release, our customers now have access to nearly 13 million key opinion leaders, and they can get the insights they need on those leaders from any location with our new ExpertGO mobile app.”

The new ExpertGO mobile app gives field medical leaders and medical science liaisons (MSLs) access to the latest intelligence, scientific activity and collaborator insights on experts around the globe. The ability to access these insights when and where needed is particularly valuable for MSLs, most of whom spend the majority of their time outside of the office, where they are visiting with experts in person.

ExpertGO will be available to download on Apple and Android devices in late June at no additional cost to existing ExpertInsight customers.

As part of this latest release, Definitive Healthcare also added Brazilian expert data to the Monocl ExpertInsight database to help life sciences teams gain a deeper understanding of the South American market. The new data covers intelligence on Brazilian healthcare professionals’ (HCPs) location and specialty, using claims data.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251

Media Contacts:
Danielle Johns
djohns@definitivehc.com

Highwire PR
definitivehealthcare@highwirepr.com

MARLTON, N.J., June 14, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a commercial-stage medical device company focused on delivering our CCM therapy to people with heart failure, announced that the first implants in Europe for the newly launched Optimizer® Smart Mini device were recently completed in Italy. The company announced the launch of the new technology on April 29, 2022, and the first U.S. implants on May 10, 2022.

Dr. Stefano Guarracini, Head of Cardiology at the Synergo Casa di Cura Pierangeli Hospital in Pescara, Italy, described his experience with CCM therapy and his outlook for the Optimizer Smart Mini system after the first implant. “Starting in 2019, we had the opportunity to implant Optimizer devices in several patients with heart failure. We believe in the technology and consider CCM therapy to be the only option for many patients suffering from heart failure. We are excited now to be affiliated with the first European institution to have implanted the new Optimizer Smart Mini device and look forward to the simple but more advanced patient management experiences during implants and follow-ups going forward.”

Dr. Giovani Bisignani, with the Ospedale di Castrovillari, who completed his first implant almost simultaneously in the southern Italian province of Cosenza, said, “CCM therapy is a powerful weapon against heart failure. The cutting-edge technology of the new Optimizer Smart Mini along with its smaller, physiological shape allowed us to achieve efficient implantation and initiation of CCM therapy in even less time.”

In March 2022, the company announced that its quality management system received certification under the new European Union Medical Device Regulation. We believe that the launch of the Optimizer Smart Mini system is an example of the importance of a global infrastructure to support ongoing technology innovation and access. The new components of the Optimizer Smart Mini system are equally important across international markets, including a rechargeable battery with a 20-year life and new internal technology with improved programming and potential for remote monitoring in a smaller design to make the implant procedure easier for patients and physicians.

“The pace of this international rollout is a reflection of our commitment to delivering innovation that is relevant to patients worldwide,” said Mateusz Zelewski, MD, Impulse Dynamics’ Vice President International, “It is exciting to see how quickly we can increase access to new and better technology that offers hope for more patients living with heart failure.”

The Optimizer Smart Mini delivers CCM therapy, which consists of electric pulses applied to the heart between heartbeats and serves to enhance the performance of cardiac muscular contraction, making the heart work more efficiently without increasing the heart rate or the oxygen consumption of the cardiac muscle. CCM therapy is currently indicated in Europe to reduce hospitalizations and improve physical exercise tolerance, quality of life, and functional status for a large population of patients with systolic heart failure who remain symptomatic despite guideline-directed medical therapy.

To date, CCM therapy has already been used to treat over 7,000 patients worldwide and is available in 44 countries across the globe. The therapy has been studied in almost 2,000 patients and has appeared in more than 100 peer-reviewed journal articles. Ongoing studies are also underway to examine the safety and efficacy of CCM for patients suffering from heart failure with a left ventricular ejection fraction between 40 – 60%.

About Impulse Dynamics

Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer Smart device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.[1] To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/

Attachments

• Optimizer Smart Mini Delivery System
• Optimizer Smart Mini Delivery System With Leads to the Heart

Rex Richmond, Director (Media Relations)
Impulse Dynamics
856-642-9933
rrichmond@impulsedynamics.com

Harriss Currie, CFO (Investor Relations)
Impulse Dynamics
856-642-9933
hcurrie@impulsedynamics.com

Ian Segal, Public Relations
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

SYDNEY, June 14, 2022 (GLOBE NEWSWIRE) — It’s official. The most Instagrammed light artwork at Vivid Sydney 2022 is the Sydney Opera House Lighting of the Sails’ new digital artwork, Yarrkalpa — Hunting Ground 2021 by the Martu Artists and creative technologists Curiious.

Vivid Sydney, the annual festival of Light, Music and Ideas is one of the most Insta-worthy events in the world, transforming Sydney’s central business district (CBD) into a fusion of creativity, innovation and technology until Saturday 18 June. The 2022 festival features more than 50 light installations and projection artworks from 62 light collaborators and 114 artists from five countries, along the longest continuous Light Walk ever at 8km.

Other frontrunners for the most shared artwork on Instagram include Convergence — the largest laser installation ever seen at Vivid Sydney in the disused railway tunnel at the Goods Line; the first-ever floating Light Walk at Walsh Bay, Ephemeral Oceanic; the mesmerising giant globe Gravitational Grid in First Fleet Park, The Rocks; and Ken Done’s For Sydney With Love projection on the façade of Customs House.

Minister for Enterprise, Investment, Trade and Tourism Stuart Ayres said there was a 67 per cent increase overall in social shares using #vividsydney from 2019.

“It has already been a record-breaking year for Vivid Sydney, with the festival welcoming the largest-ever audiences over the opening weekend and bumper attendance over the Queen’s birthday long weekend,” Ayres said.

“Visitors are also sharing their experiences at Vivid Sydney more than ever across their social channels, with First Nations digital artwork, Yarrkalpa — Hunting Ground 2021, the most photographed and shared. I encourage everyone to keep posting and sharing their personal experiences right up until the lights are turned off on 18 June.”

Festival Director Gill Minervini said the variety of light artworks and projections on the Light Walk this year ensured there was a real cross section of artistic highlights from across the Light program.

“I really enjoy watching what captivates our audiences on the Light Walk and I’m thrilled to see so many different genres of Light art appealing to everyone who experiences the festival. It’s great to see some of my personal favourites including For Sydney With Love by Ken Done and Spinifex Group; the interactive projection Vivid Reflections on the Central Station clocktower by The Electric Canvas; and the glorious reflective artwork Temple by Leila Jeffreys receiving so much love on social media.”

In 2022, 11 Sydney CBD locations are ignited, two of which are new, with Circular Quay, Sydney CBD, The Rocks, Walsh Bay, Barangaroo, Darling Harbour, Darling Square, Darling Quarter, The Goods Line, Central Train Station, Luna Park and Taronga Zoo, all coming to life with a mesmerising kaleidoscope of light artworks to wow visitors and locals alike.

Staged over 23 nights, the festival will deliver mesmerising art displays, 3D light projections, uplifting live music performances and deep-dive discussions from the world’s brightest minds.

The full list of the 10 most Instagrammed light artworks at Vivid Sydney 2022 are:

1.  Yarrkalpa — Hunting Ground 2021, Sydney Opera House Lighting of the Sails
2.  Convergence
3.  Ephemeral Oceanic
4.  Gravitational Grid
5.  For Sydney With Love
6.  Sydney Infinity
7.  Macula
8.  Temple 
9.  Vivid Reflections
10.  Paramount+ Drone Show

*Source:  The most Instagrammed list was compiled by Destination NSW based on assets uploaded against #vividsydney on Instagram. 

For more information on Vivid Sydney including the full program and to purchase tickets, go to www.vividsydney.com. Get social using @vividsydney #vividsydney

Media Contact:
Wayne Mitcham
Destination NSW
wayne@amio.nz

Related Images

Image 1: Yarrkalpa – Hunting Ground 2021, Sydney Opera House

Photo credit: Destination NSW

Image 2: Convergence by artist Mandylights

Photo credit: Destination NSW

Image 3: Ephemeral Oceanic by artist Atelier Sisu

Photo credit: Destination NSW

Image 4: Gravitational Grid, artist Sreelize Studio

Photo credit: Destination NSW

Image 5: For Sydney with Love – artist, Ken Done

Photo credit: Destination NSW

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Yarrkalpa – Hunting Ground 2021, Sydney Opera House

As the Global Leader in Workplace Experience, HqO Continues to Expand Critical Service Offerings to Help Improve and Enhance the Office with its Acquisition of Leesman Index

BOSTON, June 14, 2022 (GLOBE NEWSWIRE) — HqO, the industry-leading workplace experience platform, today announced the acquisition of Leesman, the world’s leader in measuring employee workplace experience. This is the second time in less than one year that HqO has expanded its global footprint and portfolio through acquisition. In November 2021, HqO acquired Office App, a leading European tenant and employee engagement platform, which expanded HqO’s services into the corporate workspace. This acquisition furthers HqO’s commitment to transforming the modern office and enabling people to connect with the places they work.

HqO is used by 57% of the Fortune 100 to enhance workplace experience, improve employee satisfaction and drive operational excellence. Active in more than 250 million square feet in 25 countries, HqO currently serves customers including J.P. Morgan, Dell, JLL, Jamestown, Grosvenor, and Gecina. Customers will benefit from robust insights to enhance HqO’s best-in-class technology and services, enabling data-driven decisions that can be directly measured to continually improve services and experiences.

The HqO Workplace Experience Platform helps companies and commercial property teams support meaningful workplaces by providing world-class experience services to help employees thrive and produce the best results. Leesman has enabled 6,410 organizations in more than 100 countries to capture employee sentiment on work environments and benchmark performance against the world’s largest workplace dataset.

“The Leesman Index has been transforming how organizations benchmark their workplace experience for more than a decade, helping some of the biggest brands in the world improve their employee experience through their rich dataset and proprietary methodologies,” said HqO CEO Chase Garbarino. “We’re thrilled to bring this excellence to our customers and look forward to offering them even more tools and services, along with the world’s biggest dataset for better, data-driven decision making in improving their workplace experience.”

“This is a huge step for Leesman,” says Tim Oldman, Founder & CEO of Leesman. “Becoming part of the HqO family will dramatically accelerate our ability to support the world’s best organizations on their data-driven workplace experience strategies. Together we can offer an unparalleled depth of insight into exactly how place impacts the people who work there, be that the home, the office, or the myriad of places in between.”

Leesman’s extensive workplace experience data, which includes nearly 1 million office respondents and nearly 300,000 home-based respondents, will augment HqO’s existing, industry-leading workplace experience offerings, providing customers access to both the world’s largest workplace experience dataset and The HqO Workplace Experience Platform, the standout leader utilized by some of the top workplaces in the world. Customers will have access to survey data – offering deep insights and specificity into what employees like, dislike, or want to see more of – which HqO’s technology and services will help implement in a truly complementary partnership. Leesman will continue to operate as an independent entity, offering customers objective surveys and benchmarking services.

About Leesman
Leesman is the world leader in measuring and analyzing the experiences of employees in their places of work. Through a series of assessment tools, Leesman captures employee sentiments on how effectively the work environments they use support them. By rating organizations’ ability to support employees in the home and in the office, performance can then be benchmarked against the world’s largest database of its kind. Their data and insight equips executives at all levels to make informed, forward-thinking decisions that allow them to mitigate risk, plan for the future, and benefit from great employee workplace experience. For more information, visit https://www.leesmanindex.com/

About HqO
HqO is transforming how people connect with each other and the places they work. The HqO Workplace Experience Platform makes it easy for companies and commercial property teams to create modern workplaces through world-class amenities and services that allow people to thrive and produce the best results. Active in over 250 million square feet in 25 countries, 57% of the Fortune 100 rely on HqO to enhance their workplace experiences, improve employee satisfaction, and drive operational excellence. For more information, visit https://www.hqo.com/.

Primary Contact: Kristin Concannon
Phone: 833-225-5476
Email: kristin.concannon@hqo.co

TEMECULA, Calif., June 14, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Ankur Arora has been named Product & Business Development Manager for Nikkiso Cryogenic Services serving Southeast Asia, New Zealand and Africa.

Ankur has broad global experience in over 30 countries and worked for nearly 20 years with Atlas Copco. His responsibilities included Business Development Manager and Global Sales & Marketing reporting to Germany, based in Auckland, New Zealand, Regional BDM & Application/Product Managers based in Shanghai. He has also served as Project Manager. A mechanical engineer, he also earned an MBA and is currently working on a DBA.

He will be responsible for the launch, sales and solutions related to Waste Heat Recovery and Organic Rankine Cycle Power Generation, Pressure Letdown Power Recovery and more. He will report to Emile Bado, Executive VP, Marketing, and Dr. Reza Agahi, Vice President of Turbo.

“Ankur’s industry and global market experience will be of great benefit to the Group, as we work to develop the opportunities in these regions,” according to Emile Bado, Executive Vice President, Marketing.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

• Acquisition creates a global leader in out-of-hospital software solutions
• Accelerates ResMed’s SaaS strategy by extending ResMed’s position as a leading U.S. provider of SaaS solutions in out-of-hospital care settings into Germany
• MEDIFOX DAN will integrate into ResMed’s out-of-hospital SaaS business segment, expanding its solutions portfolio into new healthcare sectors including outpatient therapy
• Purchase price of approximately US$1 billion
• Upon closing, acquisition expected to be accretive to ResMed’s non-GAAP diluted earnings per share

SAN DIEGO and HILDESHEIM, Germany, June 14, 2022 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced a definitive agreement to acquire privately held MEDIFOX DAN, a German leader in out-of-hospital software solutions for providers in major settings across the care continuum, from Hg, a leading software and services investor.

MEDIFOX DAN’s clinical, financial, and operational solutions are mission-critical for those out-of-hospital care providers, including care documentation, personnel planning, administration, billing, and more – similar to the solutions of ResMed’s leading U.S. SaaS brands, MatrixCare and Brightree.

MEDIFOX DAN’s German customer base is complementary to the customers of ResMed’s U.S.-based SaaS business. In addition, the acquisition of MEDIFOX DAN builds on ResMed’s existing business in Germany as a leading provider of innovative cloud-connected medical devices that transform care for patients with sleep apnea and other respiratory conditions.

Under the leadership of Co-Managing Directors Dr. Thorsten Schliebe and Christian Städtler, the MEDIFOX DAN Group has continuously expanded its innovative product and service portfolio, advanced into new market segments, invested in a state-of-the-art system landscape and digital sales capacities, and made strategic acquisitions. With the market launch of the new software generations MD Outpatient and MD Inpatient, MEDIFOX DAN is setting new standards for the future of care and poised to accelerate the digitization of healthcare as part of the ResMed global team. It is now important to bundle strengths and use synergies to revolutionize the digitization of healthcare with combined forces.

“With the acquisition of MEDIFOX DAN, a fast-growing and innovative German healthcare software leader, we will expand ResMed’s SaaS business portfolio outside our current base in the U.S. market and strengthen our position as the global leader in healthcare software solutions for lower-cost and lower-acuity care,” said Mick Farrell, ResMed CEO. “We are excited to welcome the MEDIFOX DAN team to our global ResMed family: Our management cultures are highly aligned with a laser-focus on lowering costs, improving outcomes, and changing the course of chronic disease management. MEDIFOX DAN has a strong track record of innovation, fully aligned with our teams at Brightree, MatrixCare, and beyond. MEDIFOX DAN’s customer centricity has built strong and ongoing, growing demand for its software solutions across Germany, and we expect that momentum to continue and strengthen as we become one global team. Our MEDIFOX DAN and ResMed teams are united with the same global mission: to help many hundreds of millions of people live healthier lives outside the hospital, and preferably in their own home.”

“I’m excited about this landmark union between ResMed and MEDIFOX DAN, and the tremendous opportunities it unlocks for thousands of providers and millions of patients,” said ResMed SaaS President Bobby Ghoshal. “We’re seeing greater adoption of digital solutions across Germany as its population continues to age and severe staffing shortages continue to challenge German care providers. MEDIFOX DAN – and ResMed – are well positioned to help providers across major out-of-hospital care settings meet rising demands and ultimately help improve patient outcomes.”

“MEDIFOX DAN helps people to help people. We believe that the partnership with ResMed is a unique opportunity to fulfill this promise through the strategic perspectives of an international player on an even larger scale in the future. From now on we are part of a global company that specializes in the digitization of the healthcare system. A major benefit of this deal is the wide range of possibilities for an incredibly agile combination of a wide variety of services, from which our customers will particularly benefit in their everyday care work. We look forward to taking this next development step together and continue to support our customers in their daily work with innovative software solutions and services in the best possible way,” said MEDIFOX DAN Co-Managing Directors Dr. Thorsten Schliebe and Christian Städtler.

Stefan Margolis and Benedikt Joeris, both Partners at Hg, said: “It has been a great journey and partnership with Thorsten, Christian, and the whole MEDIFOX DAN team. We have long-recognised MEDIFOX DAN as a high-quality software business, providing crucial services to integrated care. Together we have significantly expanded MEDIFOX DAN’s offering through continued product investment and acquisitions. ResMed, whom we’ve known for many years, will be a great strategic owner to continue that innovation journey, enabling care givers to focus on people and patients.”

MEDIFOX DAN is headquartered in Hildesheim, Germany, and employs over 600 people. ResMed plans for MEDIFOX DAN to operate under its current brand within the ResMed SaaS business – as Brightree and MatrixCare do today.

Transaction Highlights
Under the agreement terms, ResMed will acquire MEDIFOX DAN for approximately US$1.0 billion (€950 million), which ResMed expects to fund with its existing credit facilities. In calendar year 2021, MEDIFOX DAN’s pro forma net revenue was approximately $83 million, with a pro forma adjusted EBITDA of approximately $35 million.

The transaction is expected to be accretive to ResMed’s non-GAAP diluted earnings per share after close.

The transaction is expected to close by the end of the second quarter of ResMed’s fiscal year 2023 (December 31, 2022), subject to regulatory clearances.

ResMed intends to retain MEDIFOX DAN’s employees, management structure, locations, and business processes. MEDIFOX DAN co-Managing Directors Dr. Thorsten Schliebe and Christian Städtler will continue in their current roles, reporting to ResMed SaaS President Bobby Ghoshal.

Evercore is serving as ResMed’s financial advisor and DLA Piper is serving as ResMed’s legal advisor.

Investor webcast
ResMed will discuss the transaction on a live webcast at 11:00 a.m. Eastern time on June 14, 2022. The live webcast can be accessed on ResMed’s Investor Relations website at investors.resmed.com. The online archive of the broadcast will be available on ResMed’s website approximately two hours after the webcast. In addition, a telephone replay of the webcast will be available approximately two hours after the call by dialing +1 877.660.6853 (U.S.) and +1 201.612.7415 (international) and entering an event confirmation number of 13730641. The telephone replay will be available until June 28, 2022.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

About MEDIFOX DAN
The MEDIFOX DAN Group, headquartered in Hildesheim, Germany, currently employs over 600 people at nine locations nationwide and specializes in the development of innovative software solutions and services for professional and non-professional care, therapeutic practices and child, family, and youth welfare facilities. In addition, digital solutions for modern training and education management – both for professional care and family caregivers – expand the group’s comprehensive product portfolio. What started as a small start-up developed into a firmly established software company. Besides holistic product solutions, MEDIFOX DAN has always been characterized by strong partnerships and innovative services. Behind MEDIFOX DAN stands a team of innovative minds, over 55 years of industry experience and cumulative expertise, that works every day to set trendsetting standards for digitization in the health and social care sector and to drive innovation forward. In short: We are more than just software.

Forward-looking statements
Statements contained in this news release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties that could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

For media	For media
Jayme Rubenstein	Laura Willig
+1 858.836.6798	+49 51 21 / 28 29 1-808
news@resmed.com	l.willig@medifoxdan.de
For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

Virtually Human Studio (VHS), the creators of the digital race horsing game ZED RUN launch Human Park – Season Zero – a metaverse experience with a focus on unique digital identity

SYDNEY, Australia, June 13, 2022 (GLOBE NEWSWIRE) — Today Virtually Human Studio (VHS Labs), creator of the incredibly popular digital horse-racing game ZED RUN, announced its pioneering blockchain-native multiplayer experience Human Park. Spectre Studio, a development house creating visually engaging 3D worlds, leads the development of Human Park on Unreal Engine, the acclaimed CG developer at the forefront of gaming.

More than just a gaming experience

While many gaming companies have struggled to break into Web3 and blockchain-based gaming, VHS Labs has combined its deep knowledge of Web3 with a commitment to gaming principles cherished by the global gaming community; with Human Park they are signaling what’s next. Human Park is a decentralized gaming platform built for the interoperable future. Customizable user avatars can be enhanced with fully interoperable NFT wearables and season-specific icons, centering game-play around the unique goals and identities of the player. Human Park synthesizes Web3 values – such as the importance of identity ownership – with traditional gaming by blending vivid in-world details with engaging community play. The game will be free to access, with optional enhanced gameplay modes accessible through user-owned NFT avatars and wearables.

“We’ve built Human Park to become more than just a gaming experience but a platform for digital ownership to flourish. This goes beyond one single game or one single purpose, this is the beginning of blended experiences and unforgettable stories told by our community. In the near future you’ll be able to take your Nood – your central avatar in the platform – and experience all kinds of worlds, games, and entertainment experiences. We are here to disrupt the space and bring something new to our community,” said Chris Laurent, CEO of Human Park.

The Mood for Noods

The launch of Human Park today is accompanied by the drop of the first themed release, Season Zero, a retro-cyberpunk world drawing inspiration from the often ambiguous relationship between good and evil. In the age of over-priced allow lists that lack any utility, Human Park has already set itself apart by airdropping NFTs of individually designed Noods to the first cohort of users. OG Noods landed in owners’ wallets on April 20, at zero cost to recipients. The secondary market value of the Noods collection has already eclipsed $1 million, per OpenSea valuations. During a time when NFT sales have slumped globally. Original Nood holders will also see the reveal of their Obelisks, a sort of ‘loot crate’, featuring claimable NFTs with unique values and in-game applications. While holding an NFT unlocks a number of exclusive opportunities and experiences, many of which are yet to be announced, it is not a prerequisite to playing the game. Human Park is free and available for anyone to explore and play.

“The Noods in Human Park are the next evolutionary step of NFT PFP projects. We’ve decided to use human-like avatars that are extremely customizable to give our community control over how they express themselves in the growing expanse of the Metaverse. We are storytellers at heart so we’re here to empower players to tell their own stories, in this way we believe we will be transforming the way people engage with and express themselves in this new internet we are all building,” said Rick Pearce, Creative Director of Spectre Studios.

For more information about how to begin playing in Human Park, please visit our Discord and follow us on Twitter. During NFT.NYC on June 22nd, Human Park will be hosting a special launch party for Season Zero.

About Human Park
Human Park is a decentralized, next-generation Web3 experience that empowers users and gamers to interpret the Metaverse, a computer-generated interactive virtual-reality space, in their own way. This platform will provide blended experiences, elevating the concept of entertainment to the next level. Human Park is the second gaming product to come out of VHS Labs and developed by Spectre Studios, and was built on Unreal Engine.

For Media Inquiry, please contact: press@humanpark.org

Media Kit: https://wiki.humanpark.io/hp-media-kit